Business Wire

ADVA

28.7.2022 07:02:06 CEST | Business Wire | Press release

Share
ADVA increases revenues for Q2 2022

ADVA (ISIN: DE0005103006, FSE: ADV), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported final financial results for Q2 2022 ended on June 30, 2022. The results have been prepared in accordance with International Financial Reporting Standards (IFRS).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220727005735/en/

Q2 2022 financial summary 1

(in thousands of EUR)

 

Q2 2022

 

Q2 2021

 

Change

 

Q1 2022

 

Change

Revenues

 

166,320

 

149,354

 

11.4%

 

170,498

 

(2.5)%

Pro forma gross profit

 

54,336

 

57,274

 

(5.1)%

 

53,405

 

1.7%

in % of revenues

 

32.7%

 

38.3%

 

(5.6) pp

 

31.3 %

 

1.4 pp

Pro forma EBIT

 

6,435

 

14,415

 

(55.4)%

 

7,812

 

(17.6)%

in % of revenues

 

3.9%

 

9.7%

 

(5.8) pp

 

4.6%

 

(0.7) pp

Operating income 2

 

4,655

 

13,036

 

(64.3)%

 

5,976

 

(22.1)%

Net income

 

7,291

 

12,001

 

(39.2)%

 

6,179

 

18.0%

 

 

 

 

 

 

 

 

 

 

 

(in thousands of EUR)

 

Jun. 30, 2022

 

Jun. 30, 2021

 

Change

 

Mar. 31, 2022

 

Change

Cash and cash equivalents

 

63,187

 

85,023

 

(25.7)%

 

73,002

 

(13.4)%

Net cash (+)/net debt (-)

 

(946)

 

3,876

 

(124.4)%

 

763

 

(224.0)%

Net working capital

183,030

 

132,767

 

37.9%

 

164,402

 

11.3%

1 Potential inconsistencies in the table values are based on rounding differences.
2 Q2 2022 including EUR 0.4 million and Q1 2022 including EUR 0.5 million extraordinary expenses.

Q2 2022 IFRS financial results

Revenues in Q2 2022 reached EUR 166.3 million, down by 2.5% from EUR 170.5 million in Q1 2022 and up by 11.4% compared to EUR 149.4 million in Q2 2021. The increase in revenues for Q2 2022 is predominantly driven by a growth in demand from network operators and internet content providers (ICPs). In addition, the stronger US dollar led to higher revenues in North America.

Pro forma gross profit in Q2 2022 increased by 1.7%, reaching EUR 54.3 million (32.7% of revenues) compared to EUR 53.4 million (31.3% of revenues) in Q1 2022 and decreased by 5.1% compared to EUR 57.3 million (38.3% of revenues) reported in Q2 2021. Gross profit was impacted by increased purchasing costs caused by the semiconductor crisis and a stronger US Dollar.

Pro forma EBIT for Q2 2022 was EUR 6.4 million (3.9% of revenues) and decreased by 17.6% compared to EUR 7.8 million (4.6% of revenues) reported in Q1 2022 and substantially declined by 55.4% from EUR 14.4 million (9.7% of revenues) in Q2 2021.

Operating income for Q2 2022 of EUR 4.7 million decreased by 22.1% from EUR 6.0 million reported for Q1 2022 and significantly decreased by 64.3% from EUR 13.0 million in Q2 2021. Operating income for Q2 2022 was impacted by extraordinary expenses in connection with the announced merger with Adtran amounting to EUR 0.4 million (Q1 2022 EUR 0.5 million and Q2 2021 EUR 0).

Net income reached EUR 7.3 million in Q2 2022, increased by 18.0% from EUR 6.2 million in Q1 2022, and considerably decreased by 39.2% from EUR 12.0 million in Q2 2021.

The company’s cash and cash equivalents totaled EUR 63.2 million, representing a decrease of EUR 9.8 million compared to EUR 73.0 million at the end of Q1 2022. Year-over-year cash and cash equivalents decreased by EUR 21.8 million from EUR 85.0 million at the end of Q2 2021. The company invested non-operating cash in measures to secure delivery.

Net debt at the end of Q2 2022 stood at EUR 0.9 million compared to a net cash position of EUR 0.8 million at the end of Q1 2022 and a net cash position of EUR 3.9 million at the end of Q2 2021.

At quarter-end, net working capital totaled EUR 183.0 million and increased by EUR 18.6 million compared to EUR 164.4 million at the end of Q1 2022 and increased significantly by EUR 50.3 million compared to EUR 132.8 million at the end of Q2 2021. The higher net working capital compared to the year-ago quarter is mainly attributable to increased inventory levels to secure the supply chain.

Management commentary

“The recent months were very exciting for us as a company,” said Brian Protiva, CEO of ADVA. “We reached several important milestones on our journey of joining forces with Adtran and advanced our operational business. Our revenues in the first half of 2022 were at a record level, and our order books are nicely filled. We still see strong customer demand paired with a high level of complexity and costs in the areas of procurement, production and logistics. This environment will continue for the foreseeable future. Our teams work tirelessly on solutions to meet market demand, and we work closely with our customers every day to provide the best possible support for their network development. So far, we’ve mastered the challenges very well and look positively towards the remainder of the year.”

“In the past quarter, we again grew compared to the year-ago quarter. This underlines the positive market environment and the tailwind we are experiencing on the demand side,” said Uli Dopfer, CFO of ADVA. “However, in the second half of the year, we will also have to deal with the challenges resulting from increased procurement costs and stressed supply chains. Despite increased inventories, our liquidity is at a satisfying EUR 63 million. Against the background of a continued strong order intake and a strengthening dollar in combination with persistently higher costs in the supply chains, we have decided to adjust the outlook for the fiscal year accordingly, which we announced in an ad-hoc notification on July 15th. We are raising our revenue guidance to between EUR 680 and 730 million and reducing our pro forma EBIT margin guidance by one percentage point to between 5% and 9%.”

2022 financial outlook

For the fiscal year 2022, ADVA expects revenues to be in the range of EUR 680 million and 730 million and a pro forma EBIT of between 5.0% and 9.0% of revenues.

The company will publish its financial results for Q3 2022 on October 27, 2022.

Conference call details

ADVA will hold a conference call for analysts and investors today, July 28, 2022, to discuss the Q2 2022 results. The company’s CEO, Brian Protiva, CTO, Christoph Glingener, and CFO, Uli Dopfer, will host the call at 3:00 p.m. CEST (9:00 a.m. EDT). A question and answer session will follow management presentations.

A corresponding presentation is available on ADVA’s website:
https://www.adva.com/en/about-us/investors/financial-results/conference-calls

The complete half-year report 2022 (January – June) is available as a PDF here:
https://www.adva.com/en/about-us/investors/financial-results/financial-reports

A replay of the call will be available here:
https://www.adva.com/en/about-us/investors/financial-results/conference-calls

Forward-looking statements

The economic projections and forward-looking statements contained in this document relate to future facts. Such projections and forward-looking statements are subject to risks that cannot be foreseen and that are beyond the control of ADVA. ADVA is therefore not in a position to make any representation as to the accuracy of economic projections and forward-looking statements or their impact on the financial situation of ADVA or the market in the shares of ADVA.

Use of pro forma financial information

ADVA provides consolidated pro forma financial results in this press release solely as supplemental financial information to help investors and the financial community make meaningful comparisons of ADVA’s operating results from one financial period to another. ADVA believes that these pro forma consolidated financial results are helpful because they exclude non-cash charges related to the stock option programs and amortization and impairment of goodwill and acquisition-related intangible assets, which are not reflective of the company’s operating results for the period presented. Additionally, non-recurring expenses related to M&A and restructuring measures are not included. This pro forma information is not prepared in accordance with IFRS and should not be considered a substitute for the historical information presented in accordance with IFRS.

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye